Research programme: chemokine receptor antagonists - Ipsen/University of Cambridge

Drug Profile

Research programme: chemokine receptor antagonists - Ipsen/University of Cambridge

Latest Information Update: 15 Oct 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Cambridge
  • Developer Ipsen; University of Cambridge
  • Class
  • Mechanism of Action Chemokine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 30 Aug 2004 No development reported - Preclinical for Inflammation in United Kingdom (unspecified route)
  • 05 Jun 2003 Beaufour-Ipsen is now called Ipsen
  • 13 Mar 2002 Preclinical trials in Inflammation in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top